معرفی
Carina Bernardo is an active Associate Researcher and Urothelial Cancer Genomics Researcher at Lund University Cancer Centre (LUCC), Lund University. Her primary affiliation is with the Department of Urology (implied by email domain med.lu.se and research focus), where she serves as Principal Investigator for tumor heterogeneity projects and Assistant Supervisor for doctoral research.
Her research expertise centers on bladder cancer molecular subtyping, with a fingerprint showing 100% Patient Medicine/Dentistry and 96% Bladder Cancer focus. Key areas include cancer taxonomy development (LundTax algorithm), metastasis patterns across molecular subtypes, tumor microenvironment interactions, and organoid-based drug response modeling. Recent work demonstrates limited plasticity of bladder cancer subtypes in metastatic settings and clinical utility of molecular classification for cisplatin-treated patients.
Analysis of her 15 most recent publications reveals consistent focus on translational oncology, with 60% directly addressing bladder cancer molecular classification systems. Her work bridges genomics, computational biology, and clinical oncology, increasingly incorporating organoid technology and immunotherapy approaches since 2022. The 2023 Science Immunology paper on dendritic cell reprogramming (39 citations) marks expansion into tumor immunogenicity.
- Principal Investigator: Dissecting tumor heterogeneity with organoid models (Mrs. Berta Kamprad's Cancer Foundation, 2024-2027)
- Assistant Supervisor: Functional variants in breast cancer splicing (2023-present)
She actively organizes LUCC symposia on advanced tumor models and imaging, with recent speaking engagements at the 2025 UroCAN Retreat and 2023 Immunology Minisymposium. Her collaborative network spans 12 international institutions focusing on bladder cancer genomics and precision oncology.
